Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.23.2
SEGMENT INFORMATION
 9 Months Ended
Jul. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2023 and 2022 and as of July 31, 2023 and October 31, 2022, in thousands:

 

    2023     2022     2023     2022  
   

For the Three Months Ended

July 31,

    

For the Nine Months Ended

July 31,

  
    2023     2022     2023     2022  
Net Loss:                                
CAR-T Therapeutics   $ (1,091 )   $ (965 )   $ (2,999 )   $ (3,975 )
Cancer Vaccines     (1,390 )     (903 )     (3,261 )     (3,684 )
Anti-Viral Therapeutics     (62 )     (904 )     (960 )     (2,565 )
Other     (5 )     (3 )     11       (18 )
Total   $ (2,548 )   $ (2,775 )   $ (7,209 )   $ (10,242 )
                                 
Total operating costs and expenses   $ 2,844     $ 2,797     $ 8,170     $ 10,266  
Less non-cash share-based compensation     (1,217 )     (1,446 )     (3,507 )     (5,546 )
Operating costs and expenses
excluding non-cash share-based
compensation		   $ 1,627     $ 1,351     $ 4,663     $ 4,720  
 Operating costs and expenses excluding
non-cash share-based compensation:		                                
CAR-T Therapeutics   $ 713     $ 421     $ 1,930     $ 1,823  
Cancer Vaccines     855       376       1,966       1,571  
Anti-Viral Therapeutics     55       552       572       1,312  
Other     4       2       195       14  
Total   $ 1,627     $ 1,351     $ 4,663     $ 4,720  

 

    July 31, 2023     October 31, 2022  
Total assets:                
CAR-T Therapeutics   $ 11,640     $ 16,921  
Cancer Vaccines     13,968       9,442  
Anti-Viral Therapeutics     898       3,811  
Other     72       238  
Total   $ 26,578     $ 30,412  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000 for the nine months ended July 31, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.